Edwards Lifesciences Corp EW
NYSE · XNYS · stock · Orthopedic, Prosthetic & Surgical Appliances & Supplies
Chart by TradingView
6/9
Piotroski F — financial health
9.6
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $6.1B | $1.1B | $4.7B | $1.3B | $10.3B |
| 2024 | $5.4B | $4.2B | $4.3B | $289.9M | $10.1B |
| 2023 | $5.0B | $1.4B | $4.0B | $642.8M | $6.7B |
| 2022 | $4.5B | $1.5B | $3.7B | $973.6M | $5.8B |
| 2021 | $5.2B | $1.5B | $4.0B | $1.4B | $5.8B |
| 2020 | $4.4B | — | $3.3B | $647.3M | $4.6B |
Why these scores methodology →
Piotroski F-score: 6/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 9.6 (safe)
- Working capital / assets 0.36
- Retained earnings / assets 1.04
- EBIT / assets 0.092
- Equity / liabilities 3.077
Source: SEC EDGAR filings · CIK 0001099800 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.